Shionogi has enrolled the first participant in Japan in its phase 3 clinical trial of oral antiviral ensitrelvir to stop the post-infection progression of Covid-19.
VBI Vaccines has started enrollment in a Phase 1 clinical study of VBI-2901, a multivalent enveloped virus-like particle (eVLP) coronavirus vaccine candidate targeting SARS, COVID-19 and MERS.
Charles River and La Jolla Institute for Immunology (LJI) are collaborating on a new project to uncover how different cells in the human immune system respond to SARS-CoV-2 in early, acute infection.
While the last two years have seen the successful development of COVID-19 vaccines, the emergence of variants highlights the speed at which the pandemic - or indeed any other virus threat - can evolve. As a result, development of novel vaccine candidates...
The World Health Organization (WHO) is assigning ‘simple, easy to say and remember’ labels to key variants of SARS-CoV-2, using letters of the Greek alphabet.
The World Health Organization (WHO) and the Swiss Confederation have launched the first WHO BioHub Facility to enhance the rapid sharing of viruses and other pathogens between laboratories and partners globally.
Following the announcement yesterday by the UK’s Health Secretary Matt Hancock that a new strain of SARS-COV-2 could be responsible for faster spread of the virus in the South East of England, Shore Capital analysts give their perspective on what is known...